Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Freegold Intersects 1.53 g/t Au over 191.3m in infill drilling at Golden Summit (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Sellas Life Sciences Group Inc SLS

Healthcare Biotechnology
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company’s lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:SLS)

SELLAS Life Sciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update

GlobeNewswire November 12, 2025

SELLAS Life Sciences Announces Presentation of Phase 2 Data of SLS009 in Combination with Azacitidine and Venetoclax in Relapsed/Refractory AML with MDS-Related Changes (AML-MR) at the 2025 American Society of Hematology (ASH) Annual Meeting

GlobeNewswire November 3, 2025

SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $31 Million in Gross Proceeds

GlobeNewswire October 27, 2025

SELLAS Life Sciences to Participate in the J.P. Morgan U.S. Opportunities Forum

GlobeNewswire October 22, 2025

SELLAS Life Sciences to Present In Vivo Preclinical Data Demonstrating Statistically Significant Survival Benefit of SLS009 in T-Cell Prolymphocytic Leukemia at the European Society for Medical Oncology (ESMO) Congress 2025

GlobeNewswire October 13, 2025

SELLAS Life Sciences Group to Host Virtual R&D Day on October 29, 2025: Advancing Novel Therapies in Acute Myeloid Leukemia (AML): An Overview of the Ongoing Phase 3 REGAL Trial of Galinpepimut-S (GPS) and SLS009 Program Update

GlobeNewswire September 30, 2025

SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $23.6 Million in Gross Proceeds

GlobeNewswire September 11, 2025

SELLAS Life Sciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update

GlobeNewswire August 12, 2025

SELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 REGAL Trial of GPS in AML Without Modification

GlobeNewswire August 7, 2025
View More News ››

Opinion & Analysis (NDAQ:SLS)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:SLS)

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS): A Pioneering

Looks like SELLAS is cooking up something big in the cancer treatment space. 50% response rate in AML with SLS009 is no joke. Especially...
MikeTester - January 24, 2025

SLS....NR bump

FDA mentioned....$1.04
Iseneschal - November 13, 2023

RE:225 $

lol what nonsense pump. did you write your nonsense and then take off? haha
unclepieman - December 30, 2020

still holding this stock

from last year,it did a reverse split,but it's trying to make a comeback,so glta shareholders.
coolfooldumbguy - February 26, 2020

Breaking News

http://jhoponline.com/ton-web-exclusives/17423-sellas-announces-promising-data-on-neuvax-in-combination-with-herceptin-in-her2-1-2-breast...
kwhistler64 - December 2, 2019

Easy double

Best double opportunity for the week
parmagiana - November 11, 2019
View more Bullboard ››

Forge Resources Corp.

Forge Resources Corp.

Forge Resources Corp. is a junior exploration company. The Company is engaged in the business of the exploration and ...
View More »